Loading
Trastuzumab is reimbursed at 60% by Viet Nam's social health insurance; this model found a year of adjuvant trastuzumab cost 519.6 million dong (22,845 US dollars) per quality-adjusted life year gained, above thresholds of one and three times GDP per head.
A Markov model from a societal perspective compared one year of adjuvant trastuzumab with chemotherapy against chemotherapy (paclitaxel) alone in early HER2-positive breast cancer, using efficacy from the N9831, NSABP B-31, HERA and BCIRG 006 trials and Vietnamese costs and utilities. The authors state that trastuzumab is included in the social health insurance benefits package with a reimbursement rate of 60%.
Trastuzumab added 888,453,971 dong (39,062 US dollars), 3.09 life years and 1.61 quality-adjusted life years, an incremental cost-effectiveness ratio of 519,616,972 dong (22,845 US dollars) per quality-adjusted life year.
Trastuzumab works in HER2-positive breast cancer; the question this paper answers for Viet Nam is price. It gives the payer the price reductions, or biosimilars and vial sharing, that would bring the medicine within common thresholds.
Shares Vietnam Social Security, Ministry of Health, Viet Nam.
Shares Trastuzumab biosimilars, Trastuzumab.
Shares Trastuzumab biosimilars, Trastuzumab, HER2-positive breast cancer.
Shares Trastuzumab biosimilars, Trastuzumab.
Shares Trastuzumab biosimilars, Trastuzumab.
Shares Trastuzumab biosimilars, Trastuzumab.
Shares Vietnam Social Security, Ministry of Health, Viet Nam.
Shares Trastuzumab biosimilars, HER2-positive breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/